An analysis of warning letters sent by regulatory agencies regarding marketing violations indicates that the current oversight of the US electronic cigarette industry by the Food and Drug Administration (FDA) may have minimal impact, according to an article published in Tobacco Control.
In 2016, the FDA announced a plan to regulate the electronic cigarette industry, which included requiring manufacturers to obtain pre-market approval (PMTA) to ensure their products protect public health before being sold.
In 2017, regulatory agencies began sending warning letters to manufacturers, retailers, and distributors regarding potential violation of rules, such as advertising to young people, selling to minors, non-compliant packaging or labeling, and lack of PMTA application.
However, little is known about who received these letters, which product types they were concerned with, the details of the violations, and their consequences. To uncover the answers, researchers from Truth Initiative evaluated the contents and recipients of publicly available FDA warning letters released in 2020 and 2021. A total of 303 warnings were issued by the FDA: 126 in 2020 and 177 as of September 9th, 2021.
An analysis shows that by the year 2021, over 98% of target companies fulfilled all three roles (manufacturer, distributor, and retailer).
Almost all of the emails (97%) were sent to small online retailers, which sales data shows are not large companies with measurable market share. The company was cited for one to three violations, with most involving failure to obtain PMTA (Post-Market Tobacco Product Applications). Between 2020 and 2021, over 56% and 99% of the violations were related to PMTA noncompliance.
More than 90% of the products are flavored e-cigarette liquids, rather than the disposable e-cigarette devices that have been shown to be most popular among young people.
The severity of the penalties ranged from product detention to product seizure and fines. During the review, it was found that the majority (72%) of the websites cited as violating regulations in 2020 were still operating, while 29% of those cited in 2021 were also still active. As the author noted, it is impossible to determine how the target companies responded or whether the FDA followed up on the consequences mentioned in the warning letters, as this information is not publicly available.
Although current research estimates that online sales account for about one-third of the market, data tells us that most young people purchase products from friends (32.3%), from another person (21.5%), or from an e-cigarette shop (22.2%),” said the authors in a statement. They added, "Prioritizing products that young people most commonly use and can obtain from various sources is crucial for curbing youth use.
The author further suggests that there is a need to establish a strong, influential, and transparent consequence for the sale of products that violate regulations necessary to protect the health of adult electronic cigarette users and prevent youth from using such products. The FDA should utilize its enforcement authority to target manufacturers, distributors, and sellers of tobacco products that have the greatest impact on youth and do not provide public health benefits.
Statement:
This article is compiled from third-party information and is intended for communication and learning within the industry.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The compilation of this article is only intended for industry exchange and research.
Due to limitations in the translation process, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.
2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.
The copyright of compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
